TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of Metformin vs. Insulin in Pregnant Overt Diabetics (MIPOD)
Brief Summary: Many women come into pregnancy with diabetes that is controlled with either Metformin or diet control; however, the current standard of care for the treatment of preexisting diabetes in pregnancy is insulin. Metformin is widely used in the non-pregnant population for glycemic control, and has been used in pregnancy for other indications without adverse maternal or fetal outcomes. What remains unproven is the ability of Metformin to adequately control glucose in women during pregnancy.

Our goal is to randomize 100 women who enter pregnancy with diabetes that is controlled by either diet or an oral agent and women who are found to have an abnormal glucose challenge test at less than 20 weeks to either standard treatment with weight based Regular and neutral protamine Hagedorn (NPH) insulin or Metformin. Our hypothesis is that Metformin will provide glycemic control that is equivalent to insulin in these women.


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo
B: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin
D: Arm Label: Glyburide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glyburide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glyburide; Assigned to Arm(s): Glyburide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis
Brief Summary: We hypothesize that supplementing maternal diet with probiotics will decrease the incidence of feeding intolerance, necrotizing enterocolitis and sepsis in preterm infants fed breastmilk.


Options:
A: Intervention Type: DRUG; Name: Probiotics; Assigned to Arm(s): N/A
B: Arm Label: Vivomixx®; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vivomixx® | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vivomixx®; Assigned to Arm(s): Vivomixx® | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: probiotics & allergy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus rhamnosus GG | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus GG; Assigned to Arm(s): probiotics & allergy
D: Arm Label: Undernourished Pregnant Women; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nourished Pregnant Women; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Overweight/obese Pregnant women; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Undernourished + Yogurt Pregnant Women; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Moringa and Lactobacillus rhamnosus GR-1 | Arm Label: Nourished + Yogurt Pregnant Women; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Moringa and Lactobacillus rhamnosus GR-1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Moringa and Lactobacillus rhamnosus GR-1; Assigned to Arm(s): Nourished + Yogurt Pregnant Women, Undernourished + Yogurt Pregnant Women

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Varenicline for Smoking Cessation: A Pilot Study
Brief Summary: The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Arm Label: No Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Intervention Type: BEHAVIORAL; Name: NH Medicaid Incentives Program; Assigned to Arm(s): Incentives, No Incentives
D: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Varenicline for Smoking Cessation: A Pilot Study
Brief Summary: The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
B: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Placebo, Varenicline
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Varenicline for Smoking Cessation: A Pilot Study
Brief Summary: The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.


Options:
A: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
B: Arm Label: Extended Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Extended Varenicline Pretreatment | Arm Label: Short-term Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Short-term Varenicline Pretreatment | Intervention Type: DRUG; Name: Extended Varenicline Pretreatment; Assigned to Arm(s): Extended Varenicline Pretreatment | Intervention Type: DRUG; Name: Short-term Varenicline Pretreatment; Assigned to Arm(s): Short-term Varenicline Pretreatment
C: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Varenicline for Smoking Cessation: A Pilot Study
Brief Summary: The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.


Options:
A: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
D: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Varenicline for Smoking Cessation: A Pilot Study
Brief Summary: The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.


Options:
A: Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Nicotine gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Bupropion+Nicotine Gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Double placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion, Bupropion+Nicotine Gum, Double placebo, Nicotine gum
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
C: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Varenicline for Smoking Cessation: A Pilot Study
Brief Summary: The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind Phase 2 Study Of Axitinib (Ag-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma
Brief Summary: Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.


Options:
A: Arm Label: placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pazopanib arm; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib arm | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo arm
B: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)
C: Arm Label: A; Type: OTHER; Interventions: Drug: axitinib | Arm Label: B; Type: OTHER; Interventions: Drug: axitinib | Arm Label: C; Type: OTHER; Interventions: Drug: axitinib | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): C
D: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation
Brief Summary: The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.


Options:
A: Arm Label: Placebo vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo vaccine | Arm Label: NicVAX vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX vaccine | Intervention Type: BIOLOGICAL; Name: Placebo vaccine; Assigned to Arm(s): Placebo vaccine
B: Arm Label: NicQb vaccine; Type: EXPERIMENTAL; Interventions: Biological: CYT002-NicQb | Arm Label: Placebo vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: CYT002-NicQb | Intervention Type: BIOLOGICAL; Name: CYT002-NicQb; Assigned to Arm(s): NicQb vaccine, Placebo vaccine
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: NicVAX conjugate vaccine; Assigned to Arm(s): 1, 2, 3, 4, 6 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 5
D: Arm Label: NicVAX; Type: EXPERIMENTAL; Interventions: Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®) | Arm Label: NicVAX Lot 2; Type: EXPERIMENTAL; Interventions: Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®) | Intervention Type: BIOLOGICAL; Name: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®); Assigned to Arm(s): NicVAX, NicVAX Lot 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Two-Arm, Randomized (2:1), Open-Label Phase II/III Study in EpCAM Positive Cancer Patients With Symptomatic Malignant Ascites Using the Trifuncitonal Bispecific Antibody Removab (Anti-EpCAM x Anti-CD3) Versus an Untreated Control Group
Brief Summary: The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.


Options:
A: Arm Label: Abagovomab; Type: EXPERIMENTAL; Interventions: Biological: Abagovomab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Abagovomab; Assigned to Arm(s): Abagovomab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BIOLOGICAL; Name: anti-EpCAM x anti-CD3 (removab); Assigned to Arm(s): N/A
C: Arm Label: Non-randomized Cvac; Type: EXPERIMENTAL; Interventions: Biological: Cvac | Arm Label: Randomized Cvac; Type: EXPERIMENTAL; Interventions: Biological: Cvac | Arm Label: Observational standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Cvac; Assigned to Arm(s): Non-randomized Cvac, Randomized Cvac
D: Arm Label: 1 Catumaxomab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Catumaxomab (Removab), Procedure: paracentesis | Arm Label: 2:; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Catumaxomab (Removab); Assigned to Arm(s): 1 Catumaxomab | Intervention Type: PROCEDURE; Name: paracentesis; Assigned to Arm(s): 1 Catumaxomab

Answer: D